Related Experiment Video
Updated: Jul 25, 2026
03:57
Electrochemotherapy of Tumours
Published on: December 15, 2008
Systemic or regional chemotherapy: does it matter and should surgeons be involved?
1Sydney Melanoma and Surgical Oncology Unit, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Journal of the Royal College of Surgeons of Edinburgh
|June 11, 1998
Summary
Tumour necrosis factor (TNF) combined with melphalan in regional perfusion therapy significantly improves outcomes for melanoma metastases. This integrated approach offers a higher response rate than melphalan alone for locally advanced tumors.
Area of Science:
- Immunology
- Oncology
- Regional Cancer Therapy
Background:
- Tumour necrosis factor (TNF) is an anti-cancer agent with high toxicity for systemic use.
- TNF is relatively ineffective as a standalone treatment.
- Closed-circuit perfusion techniques enhance TNF efficacy.
Purpose of the Study:
- To evaluate the efficacy of TNF combined with melphalan in closed-circuit perfusion for melanoma metastases.
- To compare the response rates of combined therapy versus melphalan alone.
Main Methods:
- Utilized closed-circuit perfusion technique.
- Administered TNF in conjunction with melphalan.
- Focused on multiple melanoma metastases confined to a limb.
Main Results:
- Achieved an 80% response rate when TNF was used with melphalan.
- Melphalan alone yielded a best response rate of 40%.
Conclusions:
- Integrated regional chemotherapy, specifically TNF with melphalan via perfusion, significantly improves tumor response rates.
- Highlights the importance of surgical oncologists and vascular radiologists in advanced regional cancer treatment.
